Blueprint Medicines Reports Q4 Loss, Misses Expectations
CAMBRIDGE, Mass. (AP) - Blueprint Medicines Corp. (BPMC) reported a $50 million loss in its fourth quarter. On a per-share basis, the company posted a loss of 79 cents. Analysts had predicted a loss of 70 cents per share.
Revenue for the period totaled $146.4 million, falling short of estimates of $147.5 million.
For the year, Blueprint Medicines narrowed its loss to $67.1 million, or $1.07 per share. Revenue for the full year was $508.8 million.
Blueprint Medicines shares have increased 19% year-to-date and 34% over the past 12 months.